中國生物製藥(01177.HK):治療消化道潰瘍等一線用藥“注射用艾司奧美拉唑鈉”獲藥品註冊批件
格隆匯11月27日丨中國生物製藥(01177.HK)發佈公告,由公司附屬公司江蘇正大豐海製藥有限公司開發的消化系統用藥“注射用艾司奧美拉唑鈉”(商品名稱:恩信),已獲國家藥品監督管理局頒發藥品註冊批件。
根據披露,注射用艾司奧美拉唑鈉是第四代質子泵抑制劑,是目前臨牀上抑酸產品中最新一代產品,具有快速、強效、持久的特點。該產品已被國內外多部權威指南納入其中,是治療消化道潰瘍、消化道出血等酸相關疾病的一線用藥,臨牀廣泛應用於消化內科、外科、重症醫學科(ICU)、急診等科室。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.